Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Go back to Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence| (NASDAQ: ANAB) | Delayed: 59.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.99 | 52 Week High | $ | |||
| Open | $59.99 | 52 Week Low | $ | |||
| Day High | $59.99 | P/E | N/A | |||
| Day Low | $59.99 | EPS | $ | |||
| Volume | 126 | |||||
| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 6.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.00 | 52 Week High | $18.00 | |||
| Open | $6.00 | 52 Week Low | $6.91 | |||
| Day High | $6.00 | P/E | N/A | |||
| Day Low | $6.00 | EPS | $-0.67 | |||
| Volume | 455 | |||||
